Johnson&Johnson announced today that its innovative therapeutic drug, Teretozumab Injection, has been officially approved by the National Medical Products Administration. The monotherapy is suitable for adult patients with recurrent or refractory multiple myeloma (RRMM) who have received at least three lines of treatment in the past, including a proteasome inhibitor, an immune modulator, and an anti-CD38 monoclonal antibody. Telico is the first bispecific antibody approved for the treatment of RRMM, targeting B cell mature antigen (BCMA), and CD3, and has been approved for marketing in countries or regions such as the United States and the European Union. Telico is a globally pioneering, ready to use, weight based subcutaneous injection bispecific antibody that can redirect CD3+T cells to BCMA expressing myeloma cells to induce tumor cell killing. Clinical validation has shown that Telico has a higher response rate in relapsed or refractory multiple myeloma patients who have received at least third line treatment in the past, with better benefits for Chinese patients, with a total response rate (ORR) of 76.9%. Telico is the fourth product approved by Johnson&Johnson in China for the treatment of multiple myeloma, further enriching its leading product portfolio in the field of multiple myeloma and hematological tumor treatment, allowing more patients to have the opportunity to achieve functional cure. Multiple myeloma is the second most common malignant tumor in the field of hematological tumors in China. As a highly heterogeneous hematological tumor, almost all patients will face recurrence or drug resistance during the treatment process. As the disease progresses, the more frequent the patient relapses, the higher the difficulty of subsequent treatment, and the depth of relief after recurrence also decreases, and the duration of relief continues to shorten. Therefore, patients with recurrent or refractory multiple myeloma who have received at least third line treatment in the past urgently need more effective treatment options. Huang Chen, President of Johnson&Johnson Innovation Pharmaceuticals China, said, "Johnson&Johnson has been focusing on the field of multiple myeloma for 20 years, always committed to meeting the growing medical and health needs with high-quality innovative solutions, promoting the establishment of new treatment standards and norms in the industry, aiming to enable patients with multiple myeloma to control disease progression in the long term and have the opportunity to achieve functional cure. As the world's first bispecific antibody approved for the treatment of multiple myeloma, Telico once again confirms Johnson&Johnson's continuous efforts in innovative diagnosis and treatment of multiple myeloma, improving patient benefits.". In the future, we will continue to focus on areas with significant unmet medical needs, scientifically leading the future of medicine, and fully promoting the full lifecycle management of tumors to ensure that our breakthrough achievements can help more patients extend their lives and improve their quality of life (Lai Xin She)